Una dieta rica en omega 3 podría ayudar a ralentizar la ELA
JUEVES, 22 de junio de 2023 (HealthDay News) — Consumir ácidos grasos omega 3, como el aceite de lino y las nueces, podría ayudar a ralentizar el declive en el funcionamiento físico relacionado con la esclerosis lateral amiotrófica (ELA), sugiere una…
Learn MoreDiet Heavy in Omega-3s Might Help Slow ALS
THURSDAY, June 22, 2023 (HealthDay News) — Consuming omega-3 fatty acids like flaxseed oil and walnuts may help slow the decline in physical function related to amyotrophic lateral sclerosis (ALS), new research suggests.ALS (formerly known as Lou Geh…
Learn MoreAntisense Oligonucleotide Tofersen Reduces SOD1 in SOD1 ALS
MONDAY, Oct. 3, 2022 (HealthDay News) — The antisense oligonucleotide tofersen reduces the concentrations of superoxide dismutase 1 (SOD1) in patients with amyotrophic lateral sclerosis (ALS) associated with mutations in SOD1, but it does not improve…
Learn MoreFDA Approves New ALS Drug Despite Uncertain Data
FRIDAY, Sept. 30, 2022 (HealthDay News) — The U.S. Food and Drug Administration on Thursday gave its approval to a new drug for amyotrophic lateral sclerosis (ALS). But approval of the drug, called Relyvrio (sodium phenylbutyrate/taurursodiol), is bo…
Learn MoreFDA Approves New ALS Drug Despite Uncertain Data
FRIDAY, Sept. 30, 2022 (HealthDay News) — The U.S. Food and Drug Administration on Thursday gave its approval to a new drug for amyotrophic lateral sclerosis (ALS). But approval of the drug, called Relyvrio (sodium phenylbutyrate/taurursodiol), is bo…
Learn MoreFDA Approves New ALS Drug Despite Uncertain Data
FRIDAY, Sept. 30, 2022 (HealthDay News) — The U.S. Food and Drug Administration on Thursday gave its approval to a new drug for amyotrophic lateral sclerosis (ALS). But approval of the drug, called Relyvrio (sodium phenylbutyrate/taurursodiol), is bo…
Learn More